Biologics Market Size, Growth & Forecast Report 2033

The Biologics Market, estimated at USD 639.9 Mn in 2026, is expected to exhibit a CAGR of 10.8% and reach USD 1,311.8 Mn by 2033.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Market Dynamics

Global biologics market growth is driven by rising disease burden and an aging global population. Chronic diseases have become more widespread across both developing and developed nations. Conditions like cancer, diabetes, and heart disease pose a tremendous health burden and treatment cost. Biologics drugs have proven effective in managing several such serious and life-threatening illnesses. Medical experts predict that the proportion of elderly people will significantly rise in the near future. Older age groups have weaker immune systems and are at higher risk of developing diseases. This expanding geriatric demographic pool can boost demand for sophisticated biologic therapies. While high costs remain a challenge, ongoing R&D into biosimilars may help increase patient access and affordability over the forecast period.

Increasing incidence of chronic diseases drives the global biologics market

Global prevalence of chronic diseases has been steadily increasing over the past few decades. Some of the major chronic diseases include cancer, diabetes, cardiovascular diseases, respiratory diseases, and others. Biologics have proven to be effective treatment options for various chronic diseases. As more people are being diagnosed with chronic conditions, there will be huge demand for biologic drugs. chronic diseases currently account for most hospital admissions and deaths worldwide. This growing disease burden can drive the growth of global biologics market.

Advancements in biologic drug development and manufacturing technologies

Biopharmaceutical companies are continuously investing in R&D to develop more efficacious and targeted biologic drugs. Advancements in fields such as monoclonal antibody therapies, cell and gene therapies, recombinant proteins, and others have enabled development of biologics to treat complex diseases. Improvements in manufacturing technologies such as single-use bioreactors, continuous bioprocessing, and others have enabled large scale and cost-effective production of biologics. This has enhanced their applications to several therapeutic areas. Constant innovation and technological progress in drug development and manufacturing have expanded the market potential of biologics significantly.

Market Restraint

Biosimilars may restrain the market share of innovator biologics

As patents of many originator biologics expire, the entry of low-cost biosimilar versions poses a major challenge. Since biosimilars offer nearly equivalent therapeutic benefit at a substantially lower price, these are rapidly capturing the market share of off-patent biologics. However, the impact may vary between developed and developing markets depending on regulations governing substitution of biosimilars. Countries with stringent policies around substitution may provide innovators some protection against biosimilar erosion versus others allowing automatic substitution. Overall, increased biosimilar competition act as a restraint for sales of patented innovator biologics.

Cost of biologic drugs limits widespread adoption

High cost of various biologic drugs can act as growth barriers for the global biologics market. On an average, the prices of biologics are much higher than conventional drugs. Some of the factors contributing to their high cost include extensive R&D, complex manufacturing processes, stringent regulatory requirements for approval, and others. This makes biologics unaffordable for large patient population, especially in developing regions with budget constraints. The high cost restricts widespread adoption and global market penetration of commercially available biologics.

Market Opportunities

Increasing healthcare expenditure creates opportunities

Rising healthcare expenditure of countries around the world offers lucrative growth opportunities for biologics market. Both developing and developed nations are allocating higher budgets to strengthen their healthcare systems and improve access to advanced treatment options. This expanding healthcare spending facilitates reimbursement and affordability of costly biologics. It also encourages healthcare providers to adopt novel biologic products in treatment protocols. Growth in healthcare expenditure can drive the market growth by enhancing the demand and uptake of various biologics across regions.

Advancing technologies in oncology create a viable market

Promising medical advancements are being made in fields like cancer immunotherapy, gene therapy, targeted therapy, and others. By utilizing mechanisms such as immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapy, several innovative oncology biologics have achieved groundbreaking results in treating hard-to-address cancers. This realm holds substantial commercial opportunities considering the high prevalence and mortality associated with cancers worldwide. Strong clinical data and breakthrough designations given by regulatory agencies have boosted confidence in these novel biologic pipelines. The oncology domain hence remains an attractive segment driving growth in the biologics industry.

Market Trends

Gene and cell-based biologics are expanding into younger patient populations and previously untreatable genetic disorders. In April 2026, the FDA approved the first AAV-based gene therapy for OTOF-associated genetic hearing loss. In July 2026, the agency expanded Casgevy’s approval to patients aged two years and older with sickle cell disease or transfusion-dependent beta thalassemia. (Source: FDA)
Antibody-drug conjugates are becoming an important component of precision oncology portfolios. These products combine the targeting ability of monoclonal antibodies with potent therapeutic payloads, supporting treatment of difficult cancers. In May 2026, the FDA approved Decnupaz, a CD123-directed antibody-drug conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy.
Biologics are increasingly targeting autoimmune and rare diseases with limited treatment alternatives. Priority Review and Breakthrough Therapy pathways are supporting faster development in underserved indications. In July 2026, the FDA granted Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy, following Breakthrough Therapy Designation granted in April 2026. (Source: F. Hoffmann-La Roche Ltd)
Subcutaneous formulations and wearable delivery systems are reducing dependence on lengthy intravenous infusions. Patient-centric biologic delivery is expected to improve treatment convenience and healthcare resource utilization. In July 2026, the FDA approved subcutaneous Sarclisa Escena for multiple myeloma, including administration through the CirCLIQ on-body delivery system. (Source: FDA)
Established biologics are gaining pediatric indications and expanding across different stages of disease. Manufacturers are increasingly using lifecycle-management strategies to broaden eligible patient populations. In June 2026, the FDA approved Tzield to delay the decline of insulin production in patients aged eight to 17 years recently diagnosed with stage 3 type 1 diabetes. SKYRIZI also received pediatric approvals for psoriatic disease during 2026.
Bispecific antibodies and biologic combination regimens are moving toward broader oncology applications. Companies are evaluating immune-engaging antibodies alongside antibody-drug conjugates and other targeted biologics to improve response durability. In June 2026, the FDA accepted Roche’s supplemental Biologics License Application for the Lunsumio and Polivy combination for relapsed or refractory large B-cell lymphoma.
Rapid expansion of biosimilars is intensifying competition and improving treatment accessibility. Regulators are simplifying development requirements while approving biosimilars across oncology, diabetes, osteoporosis, and supportive care. In March 2026, the U.S. FDA reported that it had approved 82 biosimilars. New 2026 approvals included Filkri, Ponlimsi, and Langlara, referencing filgrastim, denosumab, and insulin glargine products, respectively.

Link: https://www.coherentmarketinsights.com/market-insight/biologics-market-2663

Key Developments

In July 2026, Outlook Therapeutics Inc, a biopharmaceutical company received U.S. FDA approval for LYTENAVA (bevacizumab-vikg) to treat neovascular, or wet, age-related macular degeneration. The approval makes LYTENAVA the first and only FDA-approved ophthalmic formulation of bevacizumab in the United States. Developed specifically for intravitreal administration, the therapy offers a standardized alternative to repackaged intravenous bevacizumab and expands treatment options for retina specialists and patients affected by progressive vision loss associated with this condition. (Source: Outlook Therapeutics Inc)
In July 2026, the U.S. FDA accepted Dyne Therapeutics’ biologics license application for z-rostudirsen, also known as DYNE-251, for Duchenne muscular dystrophy patients eligible for exon 51 skipping. The application received Priority Review, with a PDUFA decision date of January 21, 2027. Dyne is seeking accelerated approval based on dystrophin production as a surrogate endpoint and expects a potential U.S. launch during the first quarter of 2027, following regulatory approval.
In July 2026, Sanofi, healthcare company received U.S. FDA approval for Sarclisa Escena, a subcutaneous formulation of isatuximab-irfc for multiple myeloma. Administered through the CirCLIQ on-body injector or manual injection, it became the first anticancer treatment offering both delivery options in the United States. The system reduces administration time compared with intravenous infusion while maintaining comparable efficacy, pharmacokinetics, and safety, representing innovation in biologic cancer treatment delivery for patients and providers overall. (Source: Sanofi)
In December 2025, Biocon Biologics Ltd., a global biopharmaceutical company specializing in biosimilars, announced that the U.S. Food and Drug Administration (FDA) had approved YESINTEK (ustekinumab-kfce), a biosimilar to Janssen's Stelara (ustekinumab). YESINTEK is indicated for the treatment of several autoimmune conditions, including Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. This approval marks a significant advancement in providing more accessible treatment options for patients with chronic autoimmune diseases.
In July 2025, Lonza Group, a multinational chemicals and biotechnology company, reported a smaller-than-expected decline in first-half profits, attributed to strong performance in its Biologics unit, despite challenges in other segments
In May 2025, Biogen Inc., a leading biotechnology company specializing in neurological treatments, announced the acquisition of Human Immunology Biosciences for US$ 1.15 billion upfront, with up to US$ 650 million in potential milestone payments. This move aims to strengthen Biogen's immunology portfolio.
In May 2025, Genmab, a Denmark-based biotechnology company specializing in antibody therapeutics for cancer, acquired ProfoundBio, a biotechnology company for US$ 1.8 billion. This acquisition aims to bolster Genmab's position in the biologics market.

Key Players

Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Novartis AG, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Eli Lilly and Company, and Celltrion Healthcare Co., Ltd.